There is a peculiar moment in the life of a biotechnology company when everyone agrees on the facts and almost no one agrees on what the facts mean. The scientists have an endpoint. The clinicians have a safety profile. The lawyers have caveats. The chief financial officer has a runway. Then an investor asks a wonderfully impolite question: so what?
Burns McClellan lives inside that question. The New York consultancy advises private and public life sciences companies on investor relations, public relations and special situations. Its job is to convert scientific, clinical and regulatory progress into an account that investors, analysts, journalists and partners can understand - without sanding away the uncertainty that makes drug development what it is.
That is a narrower occupation than public relations and a stranger one than finance. A generalist agency can make a story attractive. A banker can model the market. Burns McClellan's claim is that the useful story has to survive both rooms.
The bet was specificity
Lisa Burns founded the firm in 1988 after a decade in senior roles at Fleishman-Hillard, Edelman and Burson-Marsteller. The timing deserves notice. Biotechnology was still learning what kind of industry it would become; the Human Genome Project was just beginning. Burns chose not merely healthcare communications, but a practice dedicated to the life sciences and to the awkward border between corporate narrative and investment judgment.
The company says it has since represented more than 400 businesses. Its historical roster includes large pharmaceutical names such as Baxter, Bayer, Bristol-Myers Squibb, Novartis and Teva, alongside companies that once embodied biotech's emerging class: Alkermes, Gilead Sciences, Human Genome Sciences, OSI Pharmaceuticals and SUGEN. The point is not the logo wall. It is the span - seed financing, public-market life, clinical milestones, product launch and commercialization.
“We bridge the gap between scientific innovation and the capital markets.”Burns McClellan's description of its role
A consultancy with three clocks
The scientist's clock runs from experiment to evidence. The regulator's clock runs from submission to decision. The market's clock runs from expectation to surprise. Trouble arrives when management communicates on only one of them. A result can be medically intriguing yet financially immaterial. A perfectly accurate announcement can still confuse investors if it answers the wrong comparison. A financing can be necessary and strategically sensible while feeling, to an unprepared shareholder, like an ambush.
This explains the firm's mixed bench. Burns McClellan describes experience across science, clinical development, regulatory affairs, equity research, institutional investing, investment banking, management consulting and corporate communications. The service menu follows from those overlapping clocks: investor targeting, corporate presentations, IPO preparation and S-1 support; message development, media outreach and conference programs; perception audits, executive coaching and crisis counsel.
Its customers are management teams, but the audience is a web: healthcare funds, generalist investors, sell-side analysts, bankers, journalists, physicians, patients and potential partners. Each group hears a different implication in the same sentence. Integrated IR and PR is meant to keep those implications from contradicting one another.
The product is sequence
The firm's neatest line is “strategy before tactics.” It is also a useful description of what clients can copy. Do not start with the press release. Start with the corporate objective, the evidence available, the milestone calendar and the people whose decisions matter. Only then choose the tool.
Not a slogan - a chain of evidence that explains differentiation, remaining risk and the next proof point.
Perception audits ask holders, prospective investors and analysts what they actually believe, then compare it with management's intended message.
Presentations, releases, the website, executive remarks and media outreach should carry the same positioning without becoming identical.
Speaker and media coaching matters most when a clear answer has to remain accurate under pressure.
Coverage volume is easy to count. The stronger test is whether the right audience now describes the company more accurately.
R&D Days make the sequence visible. Burns McClellan says it has executed more than 100, handling the venue and invite list but also the agenda, slides, management preparation, targeted attendance and follow-up. The event is not the product. The product is a room in which the evidence arrives in the right order.
When the first thing to fail is shared meaning
Biotech supplies cruel tests of a communications system: a trial misses an endpoint, a regulator delays a decision, a leader leaves, a hostile bidder appears. Burns McClellan explicitly offers counsel for those situations. What fails first is often not the underlying strategy but the shared interpretation of it. Employees, investors and reporters begin filling silence with different stories.
That is also what changes management's mind about hiring specialist help. Ordinary communications can be treated as an output. A high-stakes setback reveals it as infrastructure. The relevant questions become immediate: What is known? What is material? Who needs to hear it? In what order? Which claim can withstand tomorrow's data?
What the advice costs
Burns McClellan does not sell a boxed product or publish a rate card. This is tailored professional service: senior counsel, research, writing, investor outreach, event work and rapid response, assembled around the client's stage and calendar. The honest unit of cost is therefore not a seat or a subscription. It is access to experienced judgment when a small wording or timing error can travel quickly through a public market.
The model also explains the competitive field. A biotech can hire an internal IR leader; retain specialists such as Gilmartin Group, LifeSci Advisors, Westwicke/ICR or Solebury; or use a broader strategic-communications firm. Burns McClellan's difference is not that nobody else can write a release or arrange investor meetings. It is longevity, an independent specialist structure and a network concentrated in one demanding sector.
In July 2024, that longevity met its hardest transition when Lisa Burns died unexpectedly after 36 years at the company. Diana Boter, who had served as CFO and COO, became chief executive. The founder's idea remained intact: stay close to the science, understand the market, and make the explanation earn its confidence.
There is a modest lesson in this. Companies tend to imagine that a story is the decorative layer added after the real work. In life sciences, the story is the map by which outsiders inspect the work. A good map does not improve the terrain. It does something both smaller and more valuable: it lets everyone see where they actually are.